期刊文献+

ARFI与口服胃窗超声造影联合判定进展期胃癌病理分化程度

下载PDF
导出
摘要 目的探讨声辐射力脉冲成像(ARFI)与口服胃窗超声造影联合判定进展期胃癌病理分化程度的价值。方法选取2015年2.8至2017年11月期间在浙江省立同德医院治疗并经术后病理证实的56例进展期胃癌患者进行研究。根据不同病理分化程度划分为:分化组(26例)及未分化组(30例),所有患者均于术前1周进行口服胃窗超声造影及ARFI检查,测量并记录肿瘤的最大径线及ARFI值,并与术后痛理结果进行比较分析。结果未分化组的最大径线明显大于分化组,差异具有统计学意义(P〈0.05);未分化组的ARFI值明显高于分化组,差异具有统计学意义(P〈0.05);ROC曲线分析显示,以ARFI值判定未分化进展期胃癌,曲线下面积为0.861,95%置信区间为0.768~0.954,最佳临界值为4.27m/s,灵敏度为72.00%,特异度为83.90%。结论ARFI具有无创、便捷等优点,有助于客观准确地评估进展期胃癌的病理分化程度.具有一定临床价值。 Objective To investigate the diagnostic value of oral contrast ultrasonography ( OCUS ) and acoustic radiation force Imaging ( ARFI ) in the pathological differentiation of advanced gastric cancer. Methods 56 cases of patients with gastric cancer which were confirmed by pathology in Tongde Hospital of Zhejiang Province from February 2015 to November 2017 were selected. According to the different pathological differentiation, patients were divided into: the differentiation group (26 cases ) and undifferentiated group (30 cases ) . 1 week before surgery, all patients had OCUS and AIkFI examination, and the maximum diameter and ARFI value of tumor were measured and recorded, and the results were compared with pathological results. Results The maximum diameter of undifferentiated group was significantly greater than that of differentiation group, and the difference was statistically significant ( P〈0.05 ) ; ARFI value of undifferentiated group was significantly higher than that of differentiation group, and the difference was statistically significant ( P〈0.05 ) ; l?,OC curve showed the AtkFI value determine the undifferentiated advanced gastric cancer, and the area under curve was 0.861; 95% confidence interval was 0.768~0.954; cut-off value was 4.27m/s; sensitivity was 72.00%, and specificity was 83.90%. Conclusion ARFI has the advantages of non-invasive, convenient and so on. It is helpful for the objective and accurate evaluation of the pathological differentiation of advanced gastric cancer, which has certain clinical value.
出处 《浙江临床医学》 2018年第8期1443-1444,共2页 Zhejiang Clinical Medical Journal
关键词 声辐射力脉冲成像 口服胃窗超声造影 进展期胃癌 病理分化程度 Acoustic radiation force imaging Oral contrast ultrasonography Advanced gastric cancer Pathological differentiation
  • 相关文献

参考文献3

二级参考文献23

  • 1Rebecca Siegel,Deepa Naishadham,Ahmedin Jemal.Cancer statistics, 2013[J]. CA: A Cancer Journal for Clinicians . 2013 (1)
  • 2Van Cutsem E,Feyereislova A,张信华.曲妥珠单抗联合化疗与单纯化疗治疗HER2阳性晚期胃或胃食管结合部癌的Ⅲ期、开放、随机对照临床试验(ToGA试验)[J].消化肿瘤杂志(电子版).2010(03)
  • 3Charles S Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,Giuseppe Aprile,David R Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Raymond Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Minori Koshiji,Yanzhi Hsu,Astra M Liepa,Ling Gao,Jonathan D Schwartz,Josep Tabernero.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J].The Lancet.2014(9911)
  • 4Tom Waddell,Ian Chau,David Cunningham,David Gonzalez,Alicia Frances,Clare Okines,Andrew Wotherspoon,Claire Saffery,Gary Middleton,Jonathan Wadsley,David Ferry,Wasat Mansoor,Tom Crosby,Fareeda Coxon,David Smith,Justin Waters,Timothy Iveson,Stephen Falk,Sarah Slater,Clare Peckitt,Yolanda Barbachano.Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial[J].Lancet Oncology.2013(6)
  • 5Yung-Jue Bang,Young-Woo Kim,Han-Kwang Yang,Hyun Cheol Chung,Young-Kyu Park,Kyung Hee Lee,Keun-Wook Lee,Yong Ho Kim,Sang-Ik Noh,Jae Yong Cho,Young Jae Mok,Yeul Hong Kim,Jiafu Ji,Ta-Sen Yeh,Peter Button,Florin Sirzén,Sung Hoon Noh.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J].The Lancet.2012(9813)
  • 6Stephen R. Smalley,Jacqueline K. Benedetti,Daniel G. Haller,Scott A. Hundahl,Norman C. Estes,Jaffer A. Ajani,Leonard L. Gunderson,Bryan Goldman,James A. Martenson,J. Milburn Jessup,Grant N. Stemmermann,Charles D. Blanke,John S. Macdonald.Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection[J].Journal of Clinical Oncology.2012(19)
  • 7Florian Lordick,Yoon-Koo Kang,Hyun-Cheol Chung,Pamela Salman,Sang Cheul Oh,Gy?rgy Bodoky,Galina Kurteva,Constantin Volovat,Vladimir M Moiseyenko,Vera Gorbunova,Joon Oh Park,Akira Sawaki,Ilhan Celik,Heiko G?tte,Helena Melezínková,Markus Moehler.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial[J].Lancet Oncology.2013(6)
  • 8Douglas E. Guggenheim,Manish A. Shah.Gastric cancer epidemiology and risk factors[J].J Surg Oncol.2012(3)
  • 9Eric Van Cutsem,Sanne de Haas,Yoon-Koo Kang,Atsushi Ohtsu,Niall C. Tebbutt,Jian Ming Xu,Wei Peng Yong,Bernd Langer,Paul Delmar,Stefan J. Scherer,Manish A. Shah.Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial[J].Journal of Clinical Oncology.2012(17)
  • 10A.F.C. Okines,D. Gonzalez de Castro,D. Cunningham,I. Chau,R.E. Langley,L.C. Thompson,S.P. Stenning,C. Saffery,Y. Barbachano,F. Coxon,G. Middleton,D. Ferry,T. Crosby,S. Madhusudan,J. Wadsley,J. Waters,M. Hall,D. Swinson,A. Robinson,D. Smith,J.S. Reis-Filho,T.S. Waddell,L. Puckey,S. Hulkki Wilson,Z. Eltahir,M. Band,A. Wotherspoon.Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials[J].European Journal of Cancer.2013(9)

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部